<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363467</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14604</org_study_id>
    <nct_id>NCT00363467</nct_id>
  </id_info>
  <brief_title>Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation</brief_title>
  <official_title>A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ESP Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the pre-transplantation phase (following completion of consolidation chemotherapy),
      patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be
      given until a target goal for recipient body weight is obtained, or up to a maximum of 5
      days. Conditioning/Preparative therapy will follow PBSC collection for up to 30 days with
      Busulfan IV daily x 4 days; subsequent doses will be adjusted based on pharmacokinetic
      (plasma level)monitoring. Following 1 day of rest, stem cell reinfusion will begin with
      supportive care. During follow-up, patients will be monitored out to 730 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Pre- Transplantation Phase -

             1. Twenty-four to 48 hours following completion of consolidation chemotherapy,
                patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.
                Alternatively, patients may receive G-CSF alone (same dose) as mobilization
                therapy.

             2. Leukapheresis will begin day 4 of G-CSF administration and proceed according to
                institutional guidelines. Leukapheresis will continue until a target goal for
                recipient body weight is obtained, or up to a maximum of 5 days. A minimum
                recipient body weight is required to proceed to transplantation.

        2. Transplantation Phase

           a. Conditioning/Preparative therapy - up to 30 days following PBSC collection, patients
           will begin conditioning therapy with Busulfan IV daily x 4 days (transplantation days
           -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2; subsequent doses will be adjusted
           based on pharmacokinetic monitoring.

             -  Busulfan plasma level monitoring, collected around the first dose of busulfan b.
                Stem cell reinfusion - following 1 day of rest, previously collected autologous
                peripheral blood stem cells will be infused.

             -  The administration of supportive measures (e.g. intravenous fluids, antihistamines)
                during stem cell reinfusion will be performed according to institutional
                guidelines.

        3. Supportive care

             1. Antibiotic prophylaxis- according to hospital/institutional guidelines, and at the
                discretion of the treating physician.

             2. Growth factor support

             3. Transfusion support

             4. Prophylaxis for busulfan-induced seizures

        4. During follow-up, patients will be seen at least weekly for the first month and there
           after periodically out to 730 days posttransplant. The following medical procedures will
           be done:

             -  Medical history and physical exam (including concurrent meds, vital signs,
                performance status and weight)

             -  Standard labs

             -  Bone marrow aspirate and biopsy
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100-day Non-relapse Mortality</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>100-day non-relapse mortality is the number of participants who died before day 100 posttransplant from causes other than relapsed disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful Autologous Stem Cell Collection</measure>
    <time_frame>At time of stem cell collection</time_frame>
    <description>Number of subjects who were able to collect at least 2 million CD34+ cells/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Regimen-related Toxicity</measure>
    <time_frame>up to 100 days post translant</time_frame>
    <description>Number of participants with severe regimen-related toxicity within 2 years posttransplant. Severe regimen-related toxicity was defined as CTC (version 3)grade 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Event-free Survival</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Number of participants alive and without disease relapse at 1 year posttransplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Overall Survival</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Number of participants alive at 1 year posttransplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Autologous Hematopoietic Progenitor Cell Transplantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.
Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously.</description>
    <arm_group_label>Autologous Hematopoietic Progenitor Cell Transplantation</arm_group_label>
    <other_name>filgrastim or NeupogenR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>leukapheresis</description>
    <arm_group_label>Autologous Hematopoietic Progenitor Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2</description>
    <arm_group_label>Autologous Hematopoietic Progenitor Cell Transplantation</arm_group_label>
    <other_name>Busulfan (MyleranR, Busulfexâ„¢)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell reinfusion</intervention_name>
    <description>autologous stem cell transplant</description>
    <arm_group_label>Autologous Hematopoietic Progenitor Cell Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have had histologically confirmed diagnosis of AML, in 1st complete
             remission, by a pathologic review at the H. Lee Moffitt Cancer Center and Research
             Institute. Any induction/consolidation regimen is permitted.

          -  General Inclusion Criteria:

               1. Age 56-74

               2. Able to give informed consent

               3. Hepatic and renal function: normal bilirubin, AST and ALT less than or equal to
                  2x normal limits, serum creatinine less than or equal to 1.5x normal

               4. Left ventricular ejection fraction (LVEF) must be in normal range

               5. FEV1 AND DLCO greater than or equal to 50% predicted (at planned time of
                  transplantation)

               6. ECOG PS less than or equal to 2 (at planned time of transplantation)

          -  Disease Specific Inclusion Criteria:

               1. Adverse-risk karyotype (del 5/5q, 7/7q, 3q, greater than or equal to 3
                  abnormalities):

               2. Intermediate-risk karyotype [46 XY, +8, -Y, +6, or any other isolated (&lt;3 total)
                  non-random abnormality not included in the adverse-risk category or
                  favorable-risk category below]

          -  AML arising from antecedent hematologic disorder (e.g. MDS)

          -  Secondary AML (t-AML)

        Exclusion Criteria:

          -  Acute Promyelocytic Leukemia(FAB M3) subtype

          -  Presence of (8;21) translocation or inversion 16/t(16;16) cytogenetic phenotype (i.e.
             favorable-risk AML)

          -  Eligible for and willing to undergo matched-sibling allogeneic transplantation

          -  Greater than 2 induction regimens required to achieve complete remission

          -  Duration of &gt; 8 weeks between completion of induction chemotherapy and initiation of
             consolidation chemotherapy

          -  No prior malignancy is allowed, except for adequately treated basal cell (or squamous
             cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has
             been disease-free for at least 5 years.

          -  Prior extensive radiation therapy (&gt;25% of bone marrow reserve)

          -  Concomitant radiation therapy, chemotherapy, or immunotherapy

          -  Intrinsic impaired organ function (as stated above)

          -  Active infection

          -  Positive serum pregnancy test in women who have not yet reached menopause (no
             menstrual periods for &gt;12 months or who have not undergone tubal ligation or complete
             hysterectomy.

          -  Women who are breast-feeding

          -  Positive HIV testing

          -  Presence of CNS leukemia

          -  Uncontrolled insulin-dependent diabetes mellitus or uncompensated major thyroid or
             adrenal gland dysfunction

          -  Physical or psychiatric conditions that in the estimation of the PI or his designee
             place the patient at high-risk of toxicity or non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey E Lancet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>Moffiitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>August 9, 2010</results_first_submitted>
  <results_first_submitted_qc>August 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2011</results_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Busulfan</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation (HSCT)</keyword>
  <keyword>Dendritic cells</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>PBSC mobilization</keyword>
  <keyword>Autologous stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period May 15, 2006 through May 20, 2009; H. Lee Moffitt Cancer Center.</recruitment_details>
      <pre_assignment_details>The study did not involve a wash-out period or group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
          <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
          <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="2.828427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>100-day Non-relapse Mortality</title>
        <description>100-day non-relapse mortality is the number of participants who died before day 100 posttransplant from causes other than relapsed disease</description>
        <time_frame>100 days post transplant</time_frame>
        <population>Analysis was &quot;per protocol&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
            <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
          </group>
        </group_list>
        <measure>
          <title>100-day Non-relapse Mortality</title>
          <description>100-day non-relapse mortality is the number of participants who died before day 100 posttransplant from causes other than relapsed disease</description>
          <population>Analysis was &quot;per protocol&quot;</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Successful Autologous Stem Cell Collection</title>
        <description>Number of subjects who were able to collect at least 2 million CD34+ cells/kg</description>
        <time_frame>At time of stem cell collection</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
            <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Autologous Stem Cell Collection</title>
          <description>Number of subjects who were able to collect at least 2 million CD34+ cells/kg</description>
          <population>per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Regimen-related Toxicity</title>
        <description>Number of participants with severe regimen-related toxicity within 2 years posttransplant. Severe regimen-related toxicity was defined as CTC (version 3)grade 4.</description>
        <time_frame>up to 100 days post translant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
            <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Regimen-related Toxicity</title>
          <description>Number of participants with severe regimen-related toxicity within 2 years posttransplant. Severe regimen-related toxicity was defined as CTC (version 3)grade 4.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Event-free Survival</title>
        <description>Number of participants alive and without disease relapse at 1 year posttransplant</description>
        <time_frame>1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
            <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Event-free Survival</title>
          <description>Number of participants alive and without disease relapse at 1 year posttransplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Overall Survival</title>
        <description>Number of participants alive at 1 year posttransplant</description>
        <time_frame>1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
            <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Overall Survival</title>
          <description>Number of participants alive at 1 year posttransplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Autologous Hematopoietic Progenitor Cell Transplantation</title>
          <description>G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two patients enrolled and transplanted out of 24 targeted transplant accrual goal. Due to poor enrollment study closed and no further analyses were conducted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey Lancet MD</name_or_title>
      <organization>H. Lee Moffitt Cancer Center</organization>
      <phone>813-745-6841</phone>
      <email>Jeffrey.Lancet@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

